EGFR and lung adenocarcinoma: Lung adenocarcinoma (LUAD), the most common subtype of non‐small‐cell lung cancer (NSCLC), is often driven by mutations, particularly in epidermal growth factor receptor (EGFR), that guide targeted therapy choices.